BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32775617)

  • 21. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
    Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
    Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
    González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
    J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1.
    Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Olafsen T; Warner SG; Fong Y; Woo Y
    Mol Ther Oncolytics; 2022 Mar; 24():331-339. PubMed ID: 35118191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Menstrual Blood-Derived Stem Cells as Delivery Vehicles for Oncolytic Adenovirus Virotherapy for Colorectal Cancer.
    Guo Y; Zhang Z; Xu X; Xu Z; Wang S; Huang D; Li Y; Mou X; Liu F; Xiang C
    Stem Cells Dev; 2019 Jul; 28(13):882-896. PubMed ID: 30991894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.
    Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA
    Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice.
    Morales-Molina Á; Gambera S; Cejalvo T; Moreno R; Rodríguez-Milla MÁ; Perisé-Barrios AJ; García-Castro J
    Cancer Immunol Immunother; 2018 Oct; 67(10):1589-1602. PubMed ID: 30066102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth.
    Hsiao WC; Sung SY; Liao CH; Wu HC; Hsieh CL
    Mol Pharm; 2012 May; 9(5):1396-408. PubMed ID: 22480282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.
    Schierer S; Hesse A; Müller I; Kämpgen E; Curiel DT; Schuler G; Steinkasserer A; Nettelbeck DM
    Int J Cancer; 2008 Jan; 122(1):219-29. PubMed ID: 17764070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.
    García-Castro J; Alemany R; Cascalló M; Martínez-Quintanilla J; Arriero Mdel M; Lassaletta A; Madero L; Ramírez M
    Cancer Gene Ther; 2010 Jul; 17(7):476-83. PubMed ID: 20168350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.
    Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Curiel DT
    J Ovarian Res; 2016 Jun; 9(1):38. PubMed ID: 27349517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
    Muscolini M; Castiello L; Palermo E; Zevini A; Ferrari M; Olagnier D; Hiscott J
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
    Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies.
    Ekeke CN; Russell KL; Joubert K; Bartlett DL; Luketich JD; Soloff AC; Guo ZS; Lotze MT; Dhupar R
    Ann Surg Oncol; 2021 May; 28(5):2715-2727. PubMed ID: 33575873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
    Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
    Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy.
    Gilchrist VH; Jémus-Gonzalez E; Said A; Alain T
    Cytokine Growth Factor Rev; 2020 Dec; 56():83-93. PubMed ID: 32690442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of oncolytic viruses for cancer therapy.
    Abd-Aziz N; Poh CL
    Transl Res; 2021 Nov; 237():98-123. PubMed ID: 33905949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
    Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
    Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.